Kenvue Inc. (NYSE:KVUE) Stock Has Average Price Target of $19.00

Kenvue Inc. (NYSE:KVUE) has been given a consensus recommendation of “Hold” by the eleven brokerages that are currently covering the firm, Marketbeat reports. Ten analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $18.75.

KVUE has been the topic of several research reports. Barclays upped their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. UBS Group lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th.

Kenvue Stock Performance

NYSE:KVUE opened at $17.72 on Tuesday. Kenvue has a twelve month low of $14.02 and a twelve month high of $20.13. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $34.04 billion, a P/E ratio of 20.37, a P/E/G ratio of 1.61 and a beta of 0.48. The company has a fifty day moving average of $18.46 and a 200-day moving average of $18.18.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. During the same period last year, the company earned $0.29 EPS. Kenvue’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were issued a dividend of $0.21 per share. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio is 96.55%.

Hedge Funds Weigh In On Kenvue

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in Kenvue by 0.9% during the 3rd quarter. GAMMA Investing LLC now owns 84,389 shares of the company’s stock valued at $1,490,000 after acquiring an additional 790 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Kenvue by 13.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 78,083 shares of the company’s stock valued at $1,379,000 after acquiring an additional 9,340 shares in the last quarter. QRG Capital Management Inc. raised its stake in Kenvue by 9.7% in the second quarter. QRG Capital Management Inc. now owns 37,095 shares of the company’s stock valued at $709,000 after purchasing an additional 3,288 shares in the last quarter. Andra AP fonden purchased a new stake in shares of Kenvue during the 2nd quarter valued at $4,030,000. Finally, HBK Investments L P raised its position in Kenvue by 33.3% during the second quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock valued at $535,080,000 after purchasing an additional 7,000,000 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc (NYSE: KVUE) is a consumer health company that develops, markets and sells self-care, skin health and essential health products. Its portfolio includes over-the-counter medicines, allergy and cold remedies, pain-relief products, oral-care items, wound-care products, baby care products and beauty brands.

Kenvue’s principal brands include Tylenol, Motrin, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s and BAND-AID. The company distributes its products through pharmacies, retailers, e-commerce channels, healthcare providers and other commercial outlets in markets around the world.

Kenvue was formed through the separation of Johnson & Johnson’s consumer health business and became an independent publicly traded company in 2023.